On The Pen GLP-1 News

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.
We discuss:
✅ Medicare Bridge Program eligibility requirements
✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates
✅ BMI and comorbidity qualifications
✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access
✅ How Medicare patients can obtain GLP-1 medications
✅ Why obesity is finally being treated as a chronic disease
✅ The future of obesity medicine and Medicare coverage
✅ Concerns about access to care vs access to medication
✅ Muscle loss, nutrition, strength training, and healthy weight loss
✅ The Treat and Reduce Obesity Act (TROA)
This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.
📖 Read more obesity medicine news at Obesity.News
🔗 All links: linktr.ee/manonthemounjaro
#GLP1 #Medicare #Zepbound #Wegovy #Obesity #WeightLoss #ObesityMedicine #MedicareBridgeProgram #Tirzepatide #Semaglutide #Foundayo #Orforglipron #Prediabetes #Type2Diabetes #WeightManagement #AngelaFitch #OnThePen #MedicareCoverage #GLP1News #ObesityTreatment #HealthcarePolicy #WeightLossMedication #ChronicDisease #Mounjaro #Retatrutide #Lilly #NovoNordisk #ObesityAdvocacy #GLP1Community #MedicarePatients

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.

We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!

From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?

In this episode:

✅ Survodutide obesity and liver fat reduction data
✅ Mazdutide Phase 3 obesity and diabetes results
✅ UBT251 triple agonist weight loss data
✅ Berobenatide (MET-097) long-acting GLP-1 updates
✅ CagriSema diabetes and obesity trial results
✅ Zenagamtide (Amycretin) injectable and oral development
✅ Petrelintide amylin agonist info
✅ Future GLP-1, GIP, glucagon, and amylin therapies

The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.

Read more obesity medicine news at obesity.news

🔗 Linktree: linktr.ee/manonthemounjaro

#ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.

otplinks.com

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.
What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?
We dig into:
Lilly's decision to stop disclosing its Phase 1 pipeline
The Camurus fluid crystal technology deal and what it means for long-acting GLP-1s
Eloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicine
How eloralintide compares to Novo Nordisk's cagrilintide
Why the future of obesity treatment is a toolbox, not a scoreboard
The access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gaps
Retatrutide, quintuple agonists, and what's coming out of ADA 2026
If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.
🔔 Subscribe for weekly updates on obesity medicine, GLP-1 news, and what it all means for patients.
💊 Sponsored by Shed — visit TryShed.com and use code OTP25 to save 25% on obesity care.